Dr. Reddy's Laboratories secured European Commission approval for AVT03, a biosimilar to Prolia and Xgeva, for osteoporosis and bone complications. This significant milestone, following a positive CHMP recommendation, allows marketing across EU member states and EEA countries. Dr. Reddy's, in partnership with Alvotech, will commercialize the drug under brands Acyvbra and Xbonzy.

Dr. Reddy's Laboratories Ltd.'s price crossed above 50Day SMA today

Dr Reddy's gets marketing authorisation for biosimilar fromEuropean Commission

Business Line | 24 Nov 2025

Dr. Reddy's Laboratories Ltd.

24 Nov 2025

1258.80

0.76%

Policymakers-industry partnership vital for healthcare delivery: Dr Reddy's

Business Standard

Dr Reddy's Laboratories on Monday said partnerships between policymakers and industry are vital to build a future-ready healthcare system that serves millions. Satish Reddy, the chairman of the Hyderabad-based drug major, joined industry leaders at the sixth Pre-Budget Consultation chaired by Union Finance Minister Nirmala Sitharaman in the national capital. He shared his perspective on the importance of risk-based innovation funding to strengthen India's pharmaceutical ecosystem and accelerate breakthroughs that improve patient access and affordability. "At Dr Reddy's, we believe that partnerships between policymakers and industry are vital to building a future-ready healthcare system that serves millions," Reddy said in a post shared by the drug firm on social networking platform LinkedIn.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Nov 2025

1258.80

0.76%

Dr Reddy's Gets European Nod For Biosimilar To Treat Osteoporosis

NDTV Profit

Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures.